复星医药控股子公司获盐酸替那帕诺片上市许可
2月26日，复星医药（600196/02196）发布公告，控股子公司复星医药产业获得盐酸替那帕诺片的上市许可，该药品用于控制慢性肾脏病（CKD）成人透析患者的血清磷水平。
该药品的上市许可申请已于近日获得国家药品监督管理局批准，适应症为对磷结合剂疗效不充分或不耐受的患者。
截至2025年1月，集团针对该药品的累计研发投入约为1.8亿元。根据IQVIACHPA最新数据，2023年中国境内用于治疗慢性肾脏病成人患者的高磷血症的主要药品销售额约为16.05亿元。此次药品获批将进一步丰富公司的产品线，预计不会对现阶段业绩产生重大影响，但销售情况仍存在不确定性。
2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10